← Back to Search

Chemotherapy

Chemotherapy for Esophageal Cancer (CRATER Trial)

Phase 2
Waitlist Available
Led By Zhonglin Hao, MD, PhD
Research Sponsored by Zhonglin Hao
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

CRATER Trial Summary

This trial will study the effects of a combination of drugs and radiation therapy on cancer before and after surgery.

Eligible Conditions
  • Esophageal Cancer
  • Esophagogastric Junction Cancer

CRATER Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pathological complete response rate (pCR)
Secondary outcome measures
Major pathological response (MPR)
Progression free survival (PFS)

Side effects data

From 2014 Phase 4 trial • 45 Patients • NCT02000531
29%
Nausea
19%
Leukopenia
14%
White blood cell count decreased
14%
Vomiting
14%
Thrombocytopenia
14%
Alanine aminotransferase increased
14%
Anaemia
14%
Neutropenia
10%
Neutrophil count decreased
10%
Platelet count decreased
10%
Aspartate aminotransferase increased
5%
Dizziness
5%
Back pain
5%
Diarrhea
5%
Musculoskeletal pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Erlotinib-Chemotherapy
Chemotherapy-Erlotinib

CRATER Trial Design

1Treatment groups
Experimental Treatment
Group I: All patientExperimental Treatment4 Interventions
All patients receive Tislelizumab, q3week; chemotherapy with carboplatin and paclitaxel weekly concurrently for 5 weeks before surgery. Tislelizumab is continued q3week in all patients after surgery for a total of one year from the start of study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Carboplatin
FDA approved
Esophagectomy
2016
Completed Phase 3
~4130

Find a Location

Who is running the clinical trial?

Zhonglin HaoLead Sponsor
3 Previous Clinical Trials
48 Total Patients Enrolled
BeiGeneIndustry Sponsor
175 Previous Clinical Trials
28,814 Total Patients Enrolled
University of KentuckyOTHER
185 Previous Clinical Trials
226,642 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer
Zhonglin Hao 2022. "ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05245760.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top